Class / Patent application number | Description | Number of patent applications / Date published |
800005000 | The protein is isolated or extracted from blood or serum | 52 |
20080216181 | Novel Alcohol Dehydrogenases - The invention relates to novel polypeptides which have the biological activity of an NAD- or NADP-dependent alcohol dehydrogenase. The invention furthermore relates to nucleic acids encoding said polypeptides, to non-human hosts or host cells and to reaction systems which may be used for preparing desired products. The polypeptides of the invention are preferably used in the preparation, starting from aldehydes or ketones, of primary and enantiomerically pure secondary alcohol's which may serve as intermediates for medicaments. Alternatively, the polypeptides of the invention may also be employed in the reverse reaction, i.e. the oxidation of alcohol's with the formation of aldehydes or ketones. | 09-04-2008 |
20090064351 | TRANSGENIC BIRD PRODUCING ERYTHROPOIETIN AND METHOD OF CONSTRUCTING THE SAME - The present invention has its object to provide a transgenic bird producing erythropoietin at high concentration levels as well as a method for constructing the same. The present invention provides a G0 transgenic chimera bird as obtained by incubating a fertilized avian egg, infecting the early embryo formed after egg laying, except for the blastoderm stage immediately following egg laying, with a replication-deficient retroviral vector containing a foreign erythropoietin gene and allowing the embryo to hatch. | 03-05-2009 |
20090158449 | TRANSGENIC AVIAN WHICH HAS FOREIGN GENE CONTAINING SEQUENCE ENCODING FELINE-DERIVED PROTEIN AND METHOD FOR PRODUCTION THEREOF - The present invention has for its object to provide a transgenic bird with a foreign gene containing a feline-derived protein-encoding sequence as transferred therein, and a method of producing the same. The present invention provides a method of producing a feline-derived protein by using a transgenic bird with a method which comprises infecting an avian embryo with a replication defective retrovirus vector containing a foreign gene by microinjection thereof into the early heart or blood vessel formed in the embryo and allowing the embryo to hatch. | 06-18-2009 |
800006000 | The protein is an immunoglobulin | 49 |
20080235814 | Transgenic mammals having human Ig loci including plural VH and VK regions and antibodies produced therefrom - The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (V | 09-25-2008 |
20080282363 | METHODS FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE - An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents. | 11-13-2008 |
20090094704 | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 - Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and/or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH. | 04-09-2009 |
20090193530 | Animals, cells and methods for production of detectably-labeled antibodies - Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present. | 07-30-2009 |
20090222935 | Transgenic animals and uses thereof - In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein. | 09-03-2009 |
20090255002 | Transgenic Non-Human Animals For Producing Chimeric Antibodies - The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity. | 10-08-2009 |
20090260093 | TRANSGENIC ANIMALS EXPRESSING CHIMERIC ANTIBODIES FOR USE IN PREPARING HUMAN ANTIBODIES - The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro. | 10-15-2009 |
20090271880 | BINDING MOLECULES - The present invention relates to methods for engineering VH domains to improve their solubility and stability. The invention provides for the incorporation of defined amino acid substitutions based on 3-D structural information into the V segments of a heavy chain locus, expressing the locus in a non-human mammal and selecting soluble VH domains. Further stabilising or solubilising mutations maybe introduced as a result affinity maturation during B-cell maturation in vivo. | 10-29-2009 |
20090307787 | GENERATION OF HEAVY-CHAIN ONLY ANTIBODIES IN TRANSGENIC ANIMALS - The present invention relates to a method for the generation of V | 12-10-2009 |
20100186100 | ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES HAVING A SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1-84 - Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and/or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH. | 07-22-2010 |
20100205679 | Animals, cells and methods for production of detectably-labeled antibodies - Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present. | 08-12-2010 |
20100306863 | SCREENING, THERAPY AND DIAGNOSIS - A TREM-1 ligand is identified. This allows various derivatives to be provided/identified that are capable of binding to the TREM-1 receptor. The TREM-1 ligand or the derivatives can be used in screening for drugs/drug candidates. Substances that block or reduce binding of the TREM-1 ligand/derivative to a TREM-1 receptor may be useful for treating sepsis, particularly sepsis of bacterial or fungal origin. Antibodies to the ligand may be useful in diagnosing sepsis, particularly sepsis of bacterial or fungal origin. | 12-02-2010 |
20100306864 | POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION - Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function. | 12-02-2010 |
20100333220 | HUMAN TISSUE FACTOR-PRODUCING KNOCK-IN NON-HUMAN ANIMAL - A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene. | 12-30-2010 |
20110010781 | Method of Producing a Mouse Suitable for Engraftment, Differentiation and Proliferation of Heterologous Cells, Mouse Produced by This Method and Use of the Mouse - The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor γ-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model. | 01-13-2011 |
20110055938 | TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS - A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region. | 03-03-2011 |
20110067122 | Expression of Xenogenous (Human) Immunoglobulins in cloned, transgenic ungulates - The present invention relates to the production of a transgenic ungulate which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies. | 03-17-2011 |
20110138489 | TRANSGENIC ANIMALS EXPRESSING CHIMERIC ANTIBODIES FOR USE IN PREPARING HUMAN ANTIBODIES - The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro. | 06-09-2011 |
20110145937 | Mice That Make Heavy Chain Antibodies - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided. | 06-16-2011 |
20120047586 | POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION - Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function. | 02-23-2012 |
20120151610 | SOLUBLE "HEAVY-CHAIN ONLY" ANTIBODIES - The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework β-pleated sheet leading to increased net hydrophobicity within FR1 and an increased number of charged amino acids present in FR3. Also provided are VII domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy. | 06-14-2012 |
20120151611 | METHOD OF PRODUCING AN ANTIBODY USING A CANCER CELL - The present invention aims to provide a method for antibody preparation. The present invention is directed to a method for preparing an antibody-producing cell, which comprises the following steps:
| 06-14-2012 |
20120198575 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS - This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies. | 08-02-2012 |
20120222140 | HUMAN ARTIFICIAL CHROMOSOME VECTOR - The present invention provides a human artificial chromosome vector comprising a gene encoding the human antibody heavy chain, a gene encoding the human antibody light chain, and a gene encoding IgM heavy chain constant region derived from a nonhuman animal; and being capable of producing a human antibody with a higher efficiency when the vector is introduced into an animal. By immunizing the animal produced using a human artificial chromosome vector of the present invention with a desired antigen, a large quantity of human polyclonal antibodies can be supplied. | 08-30-2012 |
20130212719 | Humanized Rodents that Express Heavy Chain Containing VL Domains - Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains. | 08-15-2013 |
20130263293 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 10-03-2013 |
20130291134 | HUMANIZED TRANSGENIC MOUSE MODEL - This invention relates to a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multi-transgenic animal. This invention also relates to methods for screening compositions for human vaccine development. More specifically, the present invention relates to a mouse model capable of expressing human leukocyte antigens DR4 and A2, and/or human costimulatory molecules (CD80) which upon infusion of human HLA-matched hematopoietic stem cells develop a functional human immune system able to respond to vaccination with human vaccines. The invention also relates to method of producing human antibodies specific for a desired antigen using the transgenic mouse. | 10-31-2013 |
20130333057 | Humanized Non-Human Animals with Restricted Immunoglobulin Heavy Chain Loci - Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human V | 12-12-2013 |
20140013456 | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided. | 01-09-2014 |
20140026233 | TRANSGENIC PIG EXPRESSING STNFR1-FC GENES AND THE USES THEREOF - The present invention relates to a transgenic pig that expresses sTNFR1-Fc, wherein a gene encoding sTNFR1-Fc, which is a fusion protein of the extracellular domain of human soluble tumor necrosis factor receptor (sTNFR1) and an immunoglobulin Fc region, is introduced; a method for preparing the same; an organ isolated from the transgenic pig; a somatic donor cell line inserted with sTNFR1-Fc gene; a method for preparing a blood sample comprising sTNFR1-Fc; and a method for preparing human sTNFR1-Fc from the blood sample of the transgenic pig. As the transgenic pig can suppress immune response and inflammatory response by secreting an inhibitory substance that suppresses the activity of TNF-α in blood, it can be effectively used for xenograft. Furthermore, since the transgenic pig has a blood type O, it can be transplanted for suppressing inflammatory response, regardless of a blood type of recipient. | 01-23-2014 |
20140033335 | Immunoglobulin 2 - The present invention relates to a method for the generation of single chain immunoglobulins in a mammal. In particular, the present invention relates to a method for the generation of single chain camelid VHH antibodies in a mammal which undergo the process of class-switching and affinity maturation found within antibody producing B cells. Single chain antibodies generated using the method of the present invention and the uses thereof are also described. | 01-30-2014 |
20140068793 | TRANSCOBALAMIN RECEPTOR POLYPEPTIDES, NUCLEIC ACIDS, AND MODULATORS THEREOF, AND RELATED METHODS OF USE IN MODULATING CELL GROWTH AND TREATING CANCER AND COBALAMIN DEFICIENCY - The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake. In addition, the present invention provides compositions and methods for the detection, treatment, and prevention of diseases associated with deregulated cell growth, including, e.g., cancer and autoimmune disorders, including compositions and methods that inhibit cobalamin uptake. | 03-06-2014 |
20140283150 | Animal Models and Therapeutic Molecules - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 09-18-2014 |
20150033369 | ANIMALS, REPERTOIRES & METHODS - The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion. | 01-29-2015 |
20150040250 | Animal Models and Therapeutic Molecules - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 02-05-2015 |
20150059009 | METHODS FOR MAKING FULLY HUMAN BISPECIFIC ANTIBODIES USING A COMMON LIGHT CHAIN - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided. | 02-26-2015 |
20150067897 | GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS - Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2. | 03-05-2015 |
20150082466 | Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies - The present invention relates to humanisation of antibodies in vivo. The invention provides non-human vertebrates, cells, populations and methods useful for humanising chimaeric antibodies in vivo. Using the present invention it is possible straightforwardly and rapidly to obtain antigen-specific antibodies that are fully human (ie, comprising human variable and constant regions) and have undergone recombination, junctional diversification, affinity maturation and isotype switching in vivo in a non-human vertebrate system. Furthermore, such antibodies are humanised (eg, totally human)—and selected—totally in vivo, and as such the present invention harnesses in vivo filtering for expressibility, affinity and biophysical characteristics in the context of the desired human variable and constant region pairings. This is avoids problems of down-grading antibody characteristics when humanising the constant region of chimaeric antibodies in vitro. | 03-19-2015 |
20150113669 | Animal Models and Therapeutic Molecules - The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 04-23-2015 |
20150313193 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided. | 11-05-2015 |
20150334998 | Animal Models and Therapeutic Molecules - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 11-26-2015 |
20160046722 | NOVEL MEDICAMENTS COMPRISING AN ANTIBODY COMPOSITION ENRICHED WITH PREDOMINANT CHARGE ISOFORM - The present invention lies in the technical field of antibody therapies involving a mechanism of target-cell destruction by ADCC. It relates to purified antibody compositions, obtained by chromatographic fractionation of the various charge isoforms naturally present in an antibody composition and combining one or more chromatographic fractions corresponding to the predominant peak of the chromatogram, the resulting monoclonal antibody composition being enriched in said predominant peak, said peak representing at least 85% of the chromatogram of the composition obtained, for use as a medicament. | 02-18-2016 |
20160057979 | Human Lambda Light Chain Mice - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided. | 03-03-2016 |
20160081314 | Chimeric Antigen Receptors - Provided herein are methods and compositions related to chimeric antigen receptors (CARs) having antigen binding domains derived from an immunoglobulin (Ig) and constant domains derived from a T cell receptor (TCR). | 03-24-2016 |
20160150768 | Animal Models and Therapeutic Molecules | 06-02-2016 |
20160152713 | ANTIBODIES TO CD40 | 06-02-2016 |
20160157468 | TRANSGENIC NON-HUMAN MAMMAL FOR PRODUCING CHIMERIC HUMAN IMMUNOGLOBULIN E ANTIBODIES - The invention relates to a transgenic non-human mammal comprising human immunoglobulin mu and epsilon heavy-chain constant transgenes Cμ and Cε inserted in place of endogenous mu heavy-chain switch sequence Sμ, and its use for producing chimeric human immunoglobulin E antibodies specific for an antigen of interest. | 06-09-2016 |
20170233459 | Systems and Methods for the Production of Human Polyclonal Antibodies | 08-17-2017 |
20190141967 | TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS | 05-16-2019 |